Preclinical Rationale for Use of the Clinically Available Multitargeted Tyrosine Kinase Inhibitor Crizotinib in ROS1-Translocated Lung Cancer Hiroyuki.

Slides:

Advertisements

Similar presentations

Date of download: 9/17/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Differential Responses of Human Papillary Thyroid.

Advertisements

Copyright © 2007 American Medical Association. All rights reserved.

Nicotinamide Phosphoribosyltransferase: A Potent Therapeutic Target in Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor-Gene Mutation

Inducible EGFR T790M-Mediated Gefitinib Resistance in Non-small Cell Lung Cancer Cells Does Not Modulate Sensitivity to PI103 Provoked Autophagy Flavia.

Expression of LKB1 tumor suppressor in non–small cell lung cancer determines sensitivity to 2-deoxyglucose Landon J. Inge, PhD, Keith D. Coon, PhD, Michael.

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 Marie Florescu,

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

The Epidermal Growth Factor Receptor-L861Q Mutation Increases Kinase Activity without Leading to Enhanced Sensitivity Toward Epidermal Growth Factor Receptor.

Integrin dependent protein tyrosine phosphorylation is a key regulatory event in collagen IV mediated adhesion and proliferation of human lung tumor cell.

Yunguang Sun, PhD, Luigi Moretti, MD, Nicholas J

Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR- Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients.

Nicotine Induces Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor by α1 Nicotinic Acetylcholine Receptor–Mediated Activation in.

Rafal Dziadziuszko, MD, PhD, Anh T

MET Tyrosine Kinase Inhibitor Crizotinib (PF ) Shows Differential Antitumor Effects in Non-small Cell Lung Cancer According to MET Alterations

Combined treatment with cisplatin and sirolimus to enhance cell death in human mesothelioma Mor-Li Hartman, PhD, John Matthew Esposito, BA, Beow Yong.

Resistance to EGFR-TKI Can Be Mediated through Multiple Signaling Pathways Converging upon Cap-Dependent Translation in EGFR-Wild Type NSCLC Manish R.

SC17.02 Lung Cancer in China: Challenges and Perspectives

ALK FISH and IHC: You Cannot Have One without the Other

Expression of LKB1 tumor suppressor in non–small cell lung cancer determines sensitivity to 2-deoxyglucose Landon J. Inge, PhD, Keith D. Coon, PhD, Michael.

A Histone Deacetylase Inhibitor LBH589 Downregulates XIAP in Mesothelioma Cell Lines Which is Likely Responsible for Increased Apoptosis With TRAIL James.

G48A, a New KRAS Mutation Found in Lung Adenocarcinoma

Identification and Characterization of ALK Kinase Splicing Isoforms in Non–Small-Cell Lung Cancer Lorena Lobo de Figueiredo-Pontes, MD, PhD, Daisy Wing-Sze.

Inhibition of Hsp90 Leads to Cell Cycle Arrest and Apoptosis in Human Malignant Pleural Mesothelioma Junichi Okamoto, MD, PhD, Iwao Mikami, MD, PhD,

MET Increases the Sensitivity of Gefitinib-Resistant Cells to SN-38, an Active Metabolite of Irinotecan, by Up-Regulating the Topoisomerase I Activity

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 Marie Florescu,

Inducible EGFR T790M-Mediated Gefitinib Resistance in Non-small Cell Lung Cancer Cells Does Not Modulate Sensitivity to PI103 Provoked Autophagy Flavia.

Ras Pathway Activation in Malignant Mesothelioma

Combining the Multitargeted Tyrosine Kinase Inhibitor Vandetanib with the Antiestrogen Fulvestrant Enhances Its Antitumor Effect in Non-small Cell Lung.

Hepatocyte Growth Factor Induces Resistance to Anti-Epidermal Growth Factor Receptor Antibody in Lung Cancer Tadaaki Yamada, MD, PhD, Shinji Takeuchi,

Interpretation of Anti-ALK Immunohistochemistry Results

Nicotine Induces Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor by α1 Nicotinic Acetylcholine Receptor–Mediated Activation in.

Philip A. Rascoe, MD, Xiaobo Cao, MD, Jonathan C. Daniel, MD, Steven D

Multiple Acquired Resistance Mutations of the ALK Tyrosine Kinase Domain after Sequential Use of ALK Inhibitors Hsin-Yi Wang, MD Journal of Thoracic.

Hsp90 Inhibition Overcomes HGF-Triggering Resistance to EGFR-TKIs in EGFR-Mutant Lung Cancer by Decreasing Client Protein Expression and Angiogenesis

Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non– Small Cell Lung Cancer Xenograft Models Josephine Hai, PhD, Shingo Sakashita,

Aromatase Inhibitor Exemestane has Antiproliferative Effects on Human Mesothelioma Cells Daniela Stoppoloni, BSc, Luisa Salvatori, BSc, Annamaria Biroccio,

AT-101, a Pan-Bcl-2 Inhibitor, Leads to Radiosensitization of Non-small Cell Lung Cancer Luigi Moretti, MD, Bo Li, MD, Kwang Woon Kim, PhD, Heidi Chen,

Ziad Thotathil, MD, FRCR, Jeremy Long, FRACP

Lovastatin Sensitizes Lung Cancer Cells to Ionizing Radiation: Modulation of Molecular Pathways of Radioresistance and Tumor Suppression Toran Sanli,

Terameprocol (Tetra-O-Methyl Nordihydroguaiaretic Acid), an Inhibitor of Sp1-Mediated Survivin Transcription, Induces Radiosensitization in Non-small.

The Epidermal Growth Factor Receptor-L861Q Mutation Increases Kinase Activity without Leading to Enhanced Sensitivity Toward Epidermal Growth Factor Receptor.

A Phase 1/2 Trial of Ruxolitinib and Erlotinib in Patients with EGFR-Mutant Lung Adenocarcinomas with Acquired Resistance to Erlotinib Helena A. Yu,

Inhibition of β-Catenin Enhances the Anticancer Effect of Irreversible EGFR-TKI in EGFR-Mutated Non–small-cell Lung Cancer with a T790M Mutation Yosuke.

A Novel EML4-ALK Variant: Exon 6 of EML4 Fused to Exon 19 of ALK

George Blumenschein, MD, John V. Heymach, MD, PhD

Dasatinib, a small molecule inhibitor of the Src kinase, reduces the growth and activates apoptosis in pre-neoplastic Barrett's esophagus cell lines:

Inhibition of β-Catenin Enhances the Anticancer Effect of Irreversible EGFR-TKI in EGFR-Mutated Non–small-cell Lung Cancer with a T790M Mutation Yosuke.

V843I, a Lung Cancer Predisposing EGFR Mutation, Is Responsible for Resistance to EGFR Tyrosine Kinase Inhibitors Satsuki Matsushima, BSc, Kouki Ohtsuka,

A Pilot Study of Preoperative Gefitinib for Early-Stage Lung Cancer to Assess Intratumor Drug Concentration and Pathways Mediating Primary Resistance

Heterogeneity of Genetic Changes Associated with Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancer Soyeon Kim, PhD, Tae Min Kim, MD, PhD,

Triple Inhibition of EGFR, Met, and VEGF Suppresses Regrowth of HGF-Triggered, Erlotinib-Resistant Lung Cancer Harboring an EGFR Mutation Junya Nakade,

Nicotinamide Phosphoribosyltransferase: A Potent Therapeutic Target in Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor-Gene Mutation

Schedule-Dependent Interaction between the Proteosome Inhibitor Bortezomib and the EGFR-TK Inhibitor Erlotinib in Human Non-small Cell Lung Cancer Cell.

ALK Translocation in Non-small Cell Lung Cancer with Adenocarcinoma and Squamous Cell Carcinoma Markers Samuel J. Klempner, MD, David W. Cohen, MD, Daniel.

Mitotic Inhibitors Journal of Thoracic Oncology

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Coactivation of Receptor Tyrosine Kinases in Malignant Mesothelioma as a Rationale for Combination Targeted Therapy Marie Brevet, MD, PhD, Shigeki Shimizu,

Mirror Mirror on the Wall, Who Is the Fairest of Them All

EGFR delE709_T710insD: A Rare but Potentially EGFR Inhibitor Responsive Mutation in Non–Small-Cell Lung Cancer Allison Ackerman, MD, Michael A. Goldstein,

Daniel B. Costa, MD, PhD, Susumu Kobayashi, MD, PhD

MET Increases the Sensitivity of Gefitinib-Resistant Cells to SN-38, an Active Metabolite of Irinotecan, by Up-Regulating the Topoisomerase I Activity

Epithelial to Mesenchymal Transition in an Epidermal Growth Factor Receptor-Mutant Lung Cancer Cell Line with Acquired Resistance to Erlotinib Kenichi.

Highly Sensitive Detection of EGFR T790M Mutation in Pre-TKI Specimens of EGFR- Mutated NSCLC: In Cis, In Trans, or a Different Clone? Alvaro Leone, BSc.D

Romidepsin reduces histone deacetylase activity, induces acetylation of histones, inhibits proliferation, and activates apoptosis in immortalized epithelial.

Daniel B. Costa, MD, PhD, Susan E. Jorge, PhD, Jason P

Annemarie Becker, MD, PhD, Atie van Wijk, RN, Egbert F

Effects of visfatin on the cell proliferation and phosphorylation of ERK, Akt, and GSK-3β proteins in HCC cells. Effects of visfatin on the cell proliferation.

Signal Transducer and Activator of Transcription 3 as Molecular Therapy for Non–Small- Cell Lung Cancer Cheng-Yi Wang, MD, Ting-Ting Chao, PhD, Wei-Tien.

Effect of bevacizumab on the proliferation of A2780 cells.

A Review of First-Line Treatment for Small-cell Lung Cancer

Presentation transcript:

Preclinical Rationale for Use of the Clinically Available Multitargeted Tyrosine Kinase Inhibitor Crizotinib in ROS1-Translocated Lung Cancer Hiroyuki Yasuda, MD, Lorena L. de Figueiredo-Pontes, MD, PhD, Susumu Kobayashi, MD, PhD, Daniel B. Costa, MD, PhD Journal of Thoracic Oncology Volume 7, Issue 7, Pages 1086-1090 (July 2012) DOI: 10.1097/JTO.0b013e3182570919 Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Proliferation assay evaluating multitargeted tyrosine kinase inhibitors in NSCLC cell lines. Cells were plated at a density of 1500 cells/well for A549, 2500 cells/well for H3122, 5000 cells/well for H3255, and 2000 cells/well for HCC78. All experiments were performed in triplicate. A, Inhibitory profile of imatinib (0, 0.01, 0.1, and 1 μM). B, Inhibitory profile of sorafenib (0, 0.01, 0.1, and 1 μM). C, Inhibitory profile of erlotinib (0, 0.01, 0.1, and 1 μM). D, Inhibitory profile of crizotinib (0, 0.01, 0.1, and 1 μM). Results are displayed in bar columns with standard deviation (SD) in relation to cell viability. Treatment with dimethyl sulfoxide (indicated as a concentration of 0) was used as the standard for 100% cell viability in each cell line. * indicates a p < 0.05 (see text for exact p values) for erlotinib and crizotinib-treated cells. Journal of Thoracic Oncology 2012 7, 1086-1090DOI: (10.1097/JTO.0b013e3182570919) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Western blot analysis of protein extracts from cells treated with crizotinib. A549, H3122, HCC78, and H3255 cells were treated with dimethyl sulfoxide (indicated as concentration of 0), 0.1 or 1 μM of crizotinib for 24 hours. The figure shows the levels of phosphorylated ALK, total ALK (expected size of EML4-ALK E13;A20 of approximately 120kDa), phosphorylated ROS, total ROS (expected size of SLC34A2-ROS of approximately 70 kDa with three identified isoforms of 85, 70, and 59 kDa; wild-type ROS has a size of 258 kDa), phosphorylated AKT, total AKT (size of 60 kDa), phosphorylated ERK 1/2, total ERK 1/2 (sizes of 42 and 44 kDa), and actin (size of 45 kDa). Wild-type ROS was not detected in either HCC78 or H3255 (data not shown). Journal of Thoracic Oncology 2012 7, 1086-1090DOI: (10.1097/JTO.0b013e3182570919) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Western blot analysis of protein extracts from cells treated with crizotinib. A549, H3122, HCC78, and H3255 cells were treated with 1 μM of crizotinib for 48 hours (h). The figure shows levels of full-length PARP, detected by using a PARP antibody, and cleaved PARP, detected by using a cleaved PARP antibody, in these cells. PARP cleavage was only observed in H3122 and HCC78 cell extracts. PARP, Poly (adenosine diphosphate -ribose) polymerase. Journal of Thoracic Oncology 2012 7, 1086-1090DOI: (10.1097/JTO.0b013e3182570919) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions